A5048826971- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Hepatitis C virus research
- Mobile Health and mHealth Applications
- Biochemical and Molecular Research
- Plant Pathogenic Bacteria Studies
- Plant-Microbe Interactions and Immunity
- Pneumonia and Respiratory Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Essential Oils and Antimicrobial Activity
- Bacterial Genetics and Biotechnology
- Tuberculosis Research and Epidemiology
- Bacterial biofilms and quorum sensing
- Nosocomial Infections in ICU
- Trace Elements in Health
- ICT in Developing Communities
- Fungal Biology and Applications
- Pineapple and bromelain studies
- SARS-CoV-2 detection and testing
- Medication Adherence and Compliance
- Sphingolipid Metabolism and Signaling
- CRISPR and Genetic Engineering
- Influenza Virus Research Studies
- Hepatitis B Virus Studies
Johnson & Johnson (Germany)
2024
Janssen (Belgium)
2012-2023
Johnson & Johnson (United States)
2022-2023
Janssen (United States)
2019
North Middlesex Hospital
2007
Middlesex University
2007
Instituto de Salud Carlos III
2006
Red de Investigación en Sida
2006
Vrije Universiteit Brussel
1999-2005
Vlaams Instituut voor Biotechnologie
2002-2005
The rhizobacterium Pseudomonas aeruginosa 7NSK2 produces secondary metabolites such as pyochelin (Pch), its precursor salicylic acid (SA), and the phenazine compound pyocyanin. Both mutant KMPCH (Pch-negative, SA-positive) induced resistance to Botrytis cinerea in wild-type but not transgenic NahG tomato. SA-negative mutants of both strains lost capacity induce resistance. On tomato roots, produced SA phenylalanine ammonia lyase activity, while this was case for 7NSK2. In 7NSK2, is probably...
Abstract Clearance of neutrophils from inflamed sites is critical for resolution inflammation, but pathogen-driven neutrophil apoptosis can impair host defenses. We previously showed that pyocyanin, a phenazine toxic metabolite produced by Pseudomonas aeruginosa, accelerates in vitro. compared wild-type and pyocyanin-deficient strains P. aeruginosa murine model acute pneumonia. Intratracheal instillation either strain caused rapid increase bronchoalveolar lavage counts up to 18 h after...
Pseudomonas aeruginosa produces, under conditions of iron limitation, a high-affinity siderophore, pyoverdine (PVD), which is recognized at the level outer membrane by specific TonB-dependent receptor, FpvA. So far, for P. aeruginosa, three different PVDs, differing in their peptide chain, have been described (types I–III), but only FpvA receptor type I known. Two PVD-producing strains, one II and III, were mutagenized mini-TnphoA3 transposon. In each case, mutant unable to grow presence...
The failure of raltegravir (RAL) is generally associated with the selection mutations at integrase position Y143, Q148, or N155. However, a relatively high proportion failures occurs in absence these changes. Here, we report phenotypic susceptibilities to RAL and elvitegravir (EVG) for large group HIV-infected patients failing on RAL-containing regimens. Plasma from individuals regimens underwent genotypic resistance testing (Antivirogram v2.5.01; Virco). A control other was similarly...
Using a newly constructed minitransposon with pho A reporter gene in Salmonella enteritidis N mutant, we have identified an iron‐ and pH‐inducible lipoprotein sfb A, which is component of novel ABC‐type transporter system required for virulence. This located on 4 kb ‐specific chromosomal segment, constitutes new pathogenicity islet. islet encodes outer membrane protein, OmpX, contains the operon designated ABC ( ferric binding) encoding putative periplasmic iron‐binding SfbA,...
The K103N mutation in HIV-1 reverse transcriptase (RT) confers high-level resistance to current non-nucleoside inhibitors (NNRTI). prevalence and profile of with other substitutions at RT codon 103 is less well documented.K103 among over 70,000 clinical samples submitted for routine antiretroviral testing two independent centres were examined. Phenotypic profiles isolates harboring rare K103 variants the absence known NNRTI-associated mutations retrieved from Virco's correlative...
Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced was 0.6%. Phenotypic that caused high-level lopinavir (> 100-fold) cross-resistance amprenavir, whereas it hypersusceptibility saquinavir. ProI47A should thus be considered...
The phenotypic impact on etravirine susceptibility was examined in plasma specimens from 40 nonnucleoside reverse transcriptase inhibitor-experienced HIV patients with distinct inhibitor resistance-associated mutations. Some mutations produced larger reductions fold change than others. Y181C combination at least one mutation caused, average, a 12.6-fold reduced to etravirine. Two novel changes, K101H and E399D, significantly diminished susceptibility. Thus, the original list should be...
Concordance between the conventional HIV-1 phenotypic drug resistance assay, PhenoSense (PS), and vircoTYPE (vT), a assay based on prediction of phenotype, was investigated in data set from Stanford HIV Resistance database (hivdb). Depending drug, 287 902 genotype-phenotype pairs were available for comparisons. Test results (fold-change values) two assays highly correlated, with an overall mean correlation coefficient 0.90 using single PS measurements. This rose to 0.94 when vT compared...
<i>Objectives:</i> A wide array of monitoring tests is commercially available to gauge HIV-1 disease progression and the overall health status an HIV-1-infected patient. Viral load provide a picture viral activity, while CD4 cell counts shed light on immune can help physicians prevent development opportunistic infections in patients. On other hand, genotypic phenotypic resistance testing therapeutic drug optimize antiretroviral therapy. Resistance currently recommended within...
In recent years, increasing numbers of patients infected with HIV-1 non-B subtypes have been treated modern antiretroviral regimens. Therefore, a better knowledge HIV drug resistance in strains is crucial. Thus, we compared the mutational pathways involved among most common Italy (F, C, and CRF02_AG) B subtype. total, 2234 pol sequences from 1231 virologically failing Central were analyzed. The prevalence mutations protease reverse transcriptase between has evaluated. Among...
Lack of viral load monitoring ART is known to be associated with slower switch from a failing regimen and thereby higher prevalence MDR HIV-1. Many countries have continued use thymidine analogue drugs despite recommendations tenofovir in combination cytosine NNRTI as first-line ART. The effect accumulated mutations (TAMs) on phenotypic resistance over time has been poorly characterized the African setting.A retrospective analysis individuals ongoing failure between weeks 48 96 NORA...
ABSTRACT The requirement for multiple mutations protease inhibitor (PI) resistance necessitates a better understanding of the molecular basis development. novel bioinformatics determination approach presented here elaborates on genetic profiles observed in clinical human immunodeficiency virus type 1 (HIV-1) isolates. Synthetic sequences were cloned wild-type HIV-1 background to generate large number close variants, covering 69 mutation clusters between multi-PI-resistant viruses and their...
Background. The 2013–2016 Ebola epidemic in West Africa resulted accelerated development of rapid diagnostic tests for emergency outbreak preparedness. We describe the and evaluation Idylla™ prototype virus test, a fully automated sample-to-result molecular test detection Zaire ebolavirus (EBOV) Sudan (SUDV). Methods. can simultaneously detect EBOV SUDV 200 µL whole blood. sample is directly added to disposable cartridge containing all reagents preparation, RNA extraction, amplification by...
Mobile health applications called Digital Adherence Technologies (DATs), are increasingly used for improving treatment adherence among Tuberculosis patients to attain cure, and/or other chronic diseases requiring long-term and complex medication regimens. These DATs found be useful in resource-limited settings because of their cost efficiency reaching out vulnerable groups (providing pill clinic visit reminders, relevant information, motivational messages) or those staying remote rural...
A Pseudomonas fluorescens Tn5 mutant, with decreased production of the siderophore pyoverdine, was obtained, transposon inserted in hemA gene coding for glutamyl tRNA reductase, enzyme that catalyzes first step heme biosynthesis. Since this mutant leaky, a second round transposition needed to obtain completely auxotrophic precursor δ-aminolevulinate (ALA). Pyoverdine by is ALA-dependent at concentrations above those sustain growth. hemH encodes ferrochelatase showing characteristic red...
ObjectivesTo investigate the best conditions of raltegravir use to avoid selection resistance mutations in three main genetic pathways: 148, 155 and 143.
We investigated the phenotypic impact of a number uncommon amino acid substitutions at HIV-1 reverse transcriptase positions 103 and 138, which are not part etravirine resistance score were found in combination with high-impact mutation K101P. Etravirine fold changes 380-1400 for K101P + E138A/G/Q K103N/S/T V179I 12-130 (K103S +/- V179I) absence E138A/G/Q. Although effect K103S is unclear, additional position 138 seem important susceptibility.
We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V later K70G M184V, two coexisting on same viral genome. Phenotypic to lamivudine, emtricitabine, abacavir, didanosine, tenofovir was observed, whereas susceptibility zidovudine stavudine preserved.